The OSUCCC Microarray Shared Resource (MASR) was established as a "developing" Shared Resource in 1998 with genome wide expression analysis, and subsequently became a full shared resource in 1999 offering genome wide expression analysis using Affymetrix GeneChips. In November 2004, under the direction of Dr. Cario Croce, the MASR underwent a massive expansion with an infusion of capital from the CCC's institutional resources. Dr. Croce developed and built the first microarray to study microRNAs which has now been utilized by a multitude of OSUCCC investigators, by CCC investigators from the NCI and other NCI-designated cancer centers and by investigators from around the world. In 2008, MASR acquired Agilent and Exiqon microarray platforms. The MASR has thus kept up with the dramatic expansion of demands for nucleic acid-based technologies in cancer research in order to serve CCC members with an outstanding range of expression analyses. For projects utilizing microarray technologies, MASR offers multiple unique, cost effective, and comprehensive state-of-the-art services and experience, including timely experimental design consultation, genome wide expression and SNP/mutation analysis on microarray and on next-generation instrumentation, array comparative genomic hybridization (CGH) assessment of DNA and RNA integrity, quantification of DNA and RNA, design, fabrication and validation of custom microarrays, quality sample processing, hybridization, and scanning. Microarray analysis supports studies of the diverse genetic profile of cancer including analysis of genomes, epigenomes and transcriptomes in murine and human systems including both normal and malignant tissues from cancer patients. MASR uses CAarray and trains investigators to upload results to Gene Expression Omnibus (http//www/ncbi.nim.nih.gov/geo). Through outstanding institutional support and leveraging of CCSG resources, MASR has developed into a robust centralized shared resource serving the needs of OSUCCC investigators, cancer researchers in the state of Ohio, and nationally with multiple NCI cancer centers. As predicted in our last review, regular usage of the MASR has grown by over 100%, in part the result of a $2.0 m in capital investment by the CCC into the MASR equipment using institutional support. During the past 12 months, the faculty and staff of the MASR have worked with 52 OSUCCC members coming from five of the six OSUCCC scientific programs. OSUCCC members with peer-reviewed funded accounted for 71.8% of the MASR usage;overall OSUCCC usage is 88.9%. These past 12 months indicate a continuous robust demand for MASR services and predict expanded demand for MASR services.

Public Health Relevance

The Microarray Shared Resource (MASR) offers unique, cost-effective, and timely technical and professional expertise that promotes high-quality science. Services include: timely experimental design consultation, genome wide expression and SNP/mutation analysis on microarray and on nextgeneration instrumentation, array comparative genomic hybridization (CGH) assessment of DNA and RNA integrity, quantification of DNA and RNA, design, fabrication and validation of custom microarrays, quality sample processing, hybridization, and scanning. Outstanding institutional support allows the MASR to contribute to cutting edge-cancer research that integrates OSUCCC investigations across the entire University, state of Ohio, and nationally with multiple NCI Cancer Centers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601819
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$156,606
Indirect Cost
$53,913
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Salem, Galena; Ruppert, Amy S; Elder, Patrick et al. (2015) Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 56:1058-65
Niederwieser, C; Kohlschmidt, J; Volinia, S et al. (2015) Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 29:567-75
Billingsley, Caroline C; Cohn, David E; Mutch, David G et al. (2015) Polymerase ? (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121:386-94
Krok-Schoen, Jessica L; Kurta, Michelle L; Weier, Rory C et al. (2015) Clinic type and patient characteristics affecting time to resolution after an abnormal cancer-screening exam. Cancer Epidemiol Biomarkers Prev 24:162-8
Biddle, Martha J; Lennie, Terry A; Bricker, Gregory V et al. (2015) Lycopene dietary intervention: a pilot study in patients with heart failure. J Cardiovasc Nurs 30:205-12
Jin, Ming; Roth, Rachel; Rock, Jonathan B et al. (2015) The impact of tumor deposits on colonic adenocarcinoma AJCC TNM staging and outcome. Am J Surg Pathol 39:109-15
Llanos, Adana A; Pennell, Michael L; Young, Gregory S et al. (2015) No association between colorectal cancer worry and screening uptake in Appalachian Ohio. J Public Health (Oxf) 37:322-7
Nguyen, Huyen T; Jia, Guang; Shah, Zarine K et al. (2015) Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging 41:1374-82
Berman-Booty, Lisa D; Thomas-Ahner, Jennifer M; Bolon, Brad et al. (2015) Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicol Pathol 43:186-97
Durmus, Kasim; Patwa, Hafiz S; Gokozan, Hamza N et al. (2014) Functional and quality-of-life outcomes of transoral robotic surgery for carcinoma of unknown primary. Laryngoscope 124:2089-95

Showing the most recent 10 out of 1178 publications